학술논문
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study
Document Type
Artikel
Author
Source
Diabetes, obesity & metabolism. 20(2):344-351
Subject
Language
English
English
English
ISSN
1463-1326